Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Voclosporin and the Antiviral Effect Against SARS-CoV-2 in Immunocompromised Kidney Patients.
Arends EJ, Meziyerh S, Moes DJAR, Kamerling SWA, van der Kooy S, Ogando NS, Snijder EJ, van Hemert M, Visser LG, Feltkamp MCW, Claas ECJ, Rabelink TJ, van Kooten C, de Vries APJ, Teng YKO. Arends EJ, et al. Among authors: visser lg. Kidney Int Rep. 2023 Sep 7;8(12):2654-2664. doi: 10.1016/j.ekir.2023.09.003. eCollection 2023 Dec. Kidney Int Rep. 2023. PMID: 38106593 Free PMC article.
Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose.
Roozen GVT, Prins MLM, Prins C, Janse JJ, de Gruyter HLM, Pothast CR, Huisman W, Koopman JPR, Lamers OAC, Kuijer M, Myeni SK, van Binnendijk RS, Hartog GD, Heemskerk MHM, Jochems SP, Feltkamp MCW, Kikkert M, Rosendaal FR, Roestenberg M, Visser LG, Roukens AHE. Roozen GVT, et al. Among authors: visser lg. Clin Microbiol Infect. 2024 Mar 28:S1198-743X(24)00159-9. doi: 10.1016/j.cmi.2024.03.028. Online ahead of print. Clin Microbiol Infect. 2024. PMID: 38552793 Free article.
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan NH, Geers D, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Boerma A, Nijhof SH, van Dort KA, Koopmans MPG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, van Baarle D, Zaeck LM, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH ON Research Group. Tan NH, et al. Among authors: visser lg. Lancet Infect Dis. 2023 Aug;23(8):901-913. doi: 10.1016/S1473-3099(23)00140-8. Epub 2023 Apr 21. Lancet Infect Dis. 2023. PMID: 37088096 Free PMC article. Clinical Trial.
Protective efficacy of short-term infection with Necator americanus hookworm larvae in healthy volunteers in the Netherlands: a single-centre, placebo-controlled, randomised, controlled, phase 1 trial.
Hoogerwerf MA, Janse JJ, Kuiper VP, van Schuijlenburg R, Kruize YC, Sijtsma JC, Nosoh BA, Koopman JR, Verbeek-Menken PH, Westra IM, Meij P, Brienen EA, Visser LG, van Lieshout L, Jochems SP, Yazdanbakhsh M, Roestenberg M. Hoogerwerf MA, et al. Among authors: visser lg. Lancet Microbe. 2023 Dec;4(12):e1024-e1034. doi: 10.1016/S2666-5247(23)00218-5. Lancet Microbe. 2023. PMID: 38042152 Free article. Clinical Trial.
Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.
Zaeck LM, Tan NH, Rietdijk WJR, Geers D, Sablerolles RSG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Rugebregt S, Goorhuis A, Postma DF, Visser LG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, Haagmans BL, van Baarle D, Koopmans MPG; SWITCH-ON Research Group; van der Kuy PHM, GeurtsvanKessel CH, de Vries RD. Zaeck LM, et al. Among authors: visser lg. Nat Commun. 2024 May 18;15(1):4224. doi: 10.1038/s41467-024-48414-x. Nat Commun. 2024. PMID: 38762522 Free PMC article. Clinical Trial.
Fractional dose yellow fever vaccination, coming of age.
Roukens AHE, Visser LG. Roukens AHE, et al. Among authors: visser lg. Lancet Infect Dis. 2023 Aug;23(8):889-890. doi: 10.1016/S1473-3099(23)00205-0. Epub 2023 Apr 28. Lancet Infect Dis. 2023. PMID: 37127046 No abstract available.
Rapid Response to Remdesivir in Hospitalised COVID-19 Patients: A Propensity Score Weighted Multicentre Cohort Study.
Leegwater E, Dol L, Benard MR, Roelofsen EE, Delfos NM, van der Feltz M, Mollema FPN, Bosma LBE, Visser LE, Ottens TH, van Burgel ND, Arbous SM, El Bouazzaoui LH, Knevel R, Groenwold RHH, de Boer MGJ, Visser LG, Rosendaal FR, Wilms EB, van Nieuwkoop C. Leegwater E, et al. Among authors: visser le, visser lg. Infect Dis Ther. 2023 Oct;12(10):2471-2484. doi: 10.1007/s40121-023-00874-2. Epub 2023 Oct 6. Infect Dis Ther. 2023. PMID: 37801280 Free PMC article.
227 results